Atomoxetine is indicated for attention-deficit hyperactivity disorder (ADHD) in children, adolescents and adults. It is metabolized to 4- hydroxy-atomoxetine primarily by CYP2D6, which is known to have…
AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization
Signaling via the androgen receptor (AR) plays an important role in human health and disease. All currently available anti-androgens prevent ligand access to the receptor...
Population Pharmacokinetics of Dexmedetomidine (DEX) During Long-Term Continuous Infusion in Critically Ill Patients
Dexmedetomidine (DEX), a selective alpha2-adrenoceptor agonist is approved for sedation. In this study, the population pharmacokinetics (PK) of DEX during long-term (> 24 hours) infusion was…
Quantitative Prediction of Regioselectivity Toward Cytochrome P450/3A4 Using Machine Learning Approaches
In the drug discovery process, it is important to know the properties of both drug candidates and their metabolites.
A Systems Approach to Resource Allocation in an Integrated Research and Development Environment
Typically, at the beginning of a project, the scope is defined along with the timelines and budget. As project team leaders negotiate with functional managers to recruit key team members, including…
Semi-mechanistic PK/PD Model of the Effect of Odanacatib, a Cathepsin K Inhibitor, on Bone Turnover to Characterize Lumbar Spine Bone Mineral Density in Two Phase II Studies of Postmenopausal Women
Odanacatib (MK-0822), a potent, orally-active inhibitor of cathepsin K, is under clinical development for treatment of postmenopausal osteoporosis. This poster describes base model development of a...
Simulations Plus Launches Biorelevant Solubility Database
Proprietary Data Generated by Company Provides Unique Insight Needed By Drug Developers
Simulations Plus Announces Renewed Share Repurchase Program
Up to One Million Shares over 12 Months Authorized by Board of Directors
Simulations Plus Reports First Quarter FY2010 Financial Results
Record First Quarter Sees Pharmaceutical Software and Services Revenues Jump 21%, Consolidated Earnings Up 38% from 1QFY09
Development of a Physiologically Based Pharmacokinetic (PBPK) Model for Predicting Deposition and Disposition follo · g Inhaled and Intranasal Administration
The selection of a biologically active molecule as a successful inhaled therapeutic agent depends on its pharmacokinetic and safety properties...
Simulations Plus Appoints John DiBella, M.S., Manager, Marketing and Sales
New Leadership Brings Strength in Science and Engineering
Simulations Plus Appoints Robert D. Clark, PH. D., Director of Life Sciences
Dr. Clark to Join Team in January
Simulations Plus Launches Abbreviate!™ for the iPhone™
New Software Speeds Up Typing on the PopularApple® iPhoneTM and iPod Touch®
Modeling Drug Disposition of Timolol in Ocular Tissues of Rabbit following Topical Eye Drops
Recently, we reported the successful application of a novel mathematical model describing drug disposition in eye compartments to simulate disposition of clonidine after topical (eye drop) administration.
Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data
The aim of this study was to evaluate a strategy based on a physiologically based pharmacokinetic (PBPK) model for the prediction of PK profiles in human using in vitro...
Simulations Plus Reports FY2009 Financial Results
Sales up 2% to $9.143 Million, Cash up 26.9%, Earnings $0.08 Per Fully Diluted Share
Simulations Plus Sets Date for Fiscal Year 2009 Earnings Release and Conference Call
Conference Call to Be on Monday, November 30, at 4:15 PM EST